Holland-Frei Cancer MedicineRobert C. Bast, Jr., Carlo M. Croce, William N. Hait, Waun Ki Hong, Donald W. Kufe, Martine Piccart-Gebhart, Raphael E. Pollock, Ralph R. Weichselbaum, Hongyang Wang, James F. Holland John Wiley & Sons, 20. 3. 2017. - 2008 страница Holland-Frei Cancer Medicine, Ninth Edition, offers a balanced view of the most current knowledge of cancer science and clinical oncology practice. This all-new edition is the consummate reference source for medical oncologists, radiation oncologists, internists, surgical oncologists, and others who treat cancer patients.
|
Садржај
Urothelial cancer 1195 | 1237 |
Neoplasms of the vulva and vagina | 1269 |
Summer B Dewdney and Jacob Rotmensch | 1281 |
76 | 845 |
78 | 919 |
95 | 949 |
Michael E Kupferman | 1011 |
RNA tumor viruses 341 Waun Ki Hong | 28 |
Principles of radiation oncology 503 60 Agents targeting microtubules and mitotic processes | 679 |
Steven A Curley | 1129 |
List of contributors | xi |
Preface | xxvii |
1912 | |
1914 | |
1919 | |
1922 | |
Cancer epidemiology 399 51 Personalized medicine in oncology drug | 34 |
Epithelial ovarian fallopian tube and peritoneal | 1317 |
CLINICAL DISCIPLINES William N Hait and Joseph P Eder | 613 |
Molecular diagnostics in cancer 469 Peter D Cole Lisa Figueiredo and Joseph R Bertino | 625 |
Kalachand Bryan T Hennessy Robert C Bast | 637 |
Principles of surgical oncology 491 59 DNA topoisomerase targeting drugs | 665 |
Друга издања - Прикажи све
Чести термини и фразе
activity addition adenocarcinoma agents antibodies approach assessment associated benefit blood brain breast cancer carcinoma cause cells cervical chemotherapy clinical clinical trials combination common compared complete demonstrated diagnosis differentiation disease dose drug early effects et al evaluation expression factors Figure function gene growth higher human identified imatinib immune important improved incidence increased infection initial invasive involved lesions less leukemia levels limited liver lymph nodes lymphoma major malignant median metastatic models months mutations observed occur Oncol oncology outcomes overall patients phase population positive potential predictive present primary produced prognostic progression protein radiation randomized received recent receptor recurrence reduced regimens reported require resection response risk role selected showed significant specific stage studies suggest surgery surgical survival symptoms Table therapy tion tissue toxicity treated treatment trial tumor usually versus vincristine women